Therapeutic androgen receptor ligands
Nuclear Receptor Signaling · 2003
DOI: 10.1621/nrs.01009 ↗At a glance
Journal article in Nuclear Receptor Signaling, 2003. Written by George F Allan and 1 co-authors. Institution: Johnson and Johnson Pharmaceutical Research and Development, Department of Reproductive Therapeutics, Raritan, NJ 08869, USA. Cited 10 times so far (Crossref); 18 references. The full text is freely available in PubMed Central.
Abstract (original language)
In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).
Authors and institutions
- Johnson and Johnson Pharmaceutical Research and Development, Department of Reproductive Therapeutics, Raritan, NJ 08869, USA.
Cite
APA
Allan, G. F., & Sui, Z. (2003). Therapeutic androgen receptor ligands. Nuclear Receptor Signaling. https://doi.org/10.1621/nrs.01009
Vancouver
Allan GF, Sui Z. Therapeutic androgen receptor ligands. Nuclear Receptor Signaling. 2003. doi:10.1621/nrs.01009
BibTeX
@article{Allan2003,
author = {Allan, George F and Sui, Zhihua},
title = {Therapeutic androgen receptor ligands},
journal = {Nuclear Receptor Signaling},
year = {2003},
doi = {10.1621/nrs.01009}
}
EUVIMED